|8.55 0.2 (2.4%)||12-07 16:00|
|Targets||6-month :||10.67||1-year :||12.46|
|Resists||First :||9.14||Second :||10.67|
|Supports||First :||7.74||Second :||6.88|
|MAs||MA(5) :||8.09||MA(20) :||7.77|
|MA(100) :||7.43||MA(250) :||5.91|
|MACD||MACD :||-0.1||Signal :||-0.2|
|%K %D||K(14,3) :||95.9||D(3) :||84.1|
|52-week||High :||13.02||Low :||2.47|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TNGX ] has closed It is unclear right now based on current values. 59.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||8.66 - 8.69||8.69 - 8.73|
|Low:||8.1 - 8.14||8.14 - 8.18|
|Close:||8.49 - 8.55||8.55 - 8.61|
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||102 (M)|
|Shares Float||36 (M)|
|Held by Insiders||15.3 (%)|
|Held by Institutions||79.5 (%)|
|Shares Short||9,340 (K)|
|Shares Short P.Month||6,860 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||2.72|
|Profit Margin||-266.8 %|
|Operating Margin||-238.8 %|
|Return on Assets (ttm)||-15.4 %|
|Return on Equity (ttm)||-36.5 %|
|Qtrly Rev. Growth||55 %|
|Gross Profit (p.s.)||-0.8|
|Sales Per Share||0.36|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-119 (M)|
|Levered Free Cash Flow||-62 (M)|
|Price to Book value||3.14|
|Price to Sales||23.24|
|Price to Cash Flow||-7.35|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|